SkinBioTherapeutics PLC (SBTX) — Cash Flow-to-Debt Ratio
SkinBioTherapeutics PLC (SBTX) has a Cash Flow-to-Debt Ratio of -0.18x as of June 2025, meaning its operating cash flow of GBX-494.84K could theoretically repay 0% of its total liabilities (GBX2.71 Million) in one year. Check SBTX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SkinBioTherapeutics PLC Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for SkinBioTherapeutics PLC across 10 annual periods. Also explore SBTX total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for SkinBioTherapeutics PLC (2016–2025)
Year-by-year debt coverage analysis for SkinBioTherapeutics PLC. For market capitalisation and broader financial context, see market value of SkinBioTherapeutics PLC.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.48x | GBX-1.30 Million | GBX2.71 Million | ▲ +60.5% |
| 2024 | -1.21x | GBX-2.73 Million | GBX2.25 Million | ▲ +72.5% |
| 2023 | -4.41x | GBX-2.65 Million | GBX599.34K | ▼ -0.7% |
| 2022 | -4.38x | GBX-2.67 Million | GBX609.61K | ▼ -46.5% |
| 2021 | -2.99x | GBX-1.56 Million | GBX519.67K | ▼ -2.2% |
| 2020 | -2.93x | GBX-892.14K | GBX304.83K | ▲ +75.1% |
| 2019 | -11.77x | GBX-1.43 Million | GBX121.33K | ▼ -269.0% |
| 2018 | -3.19x | GBX-667.75K | GBX209.29K | ▲ +37.9% |
| 2017 | -5.14x | GBX-609.70K | GBX118.66K | ▼ -14711.9% |
| 2016 | -0.03x | GBX-1.17K | GBX33.64K | — |